IFNAR1 and systemic lupus erythematosus: The first-in-class anti-IFNAR1 antibody anifrolumab has been approved for systemic lupus erythematosus, following the positive results of the Phase 3 TULIP-1 and TULIP-2 trials and the Phase 2 MUSE study, which demonstrated improvements in global disease activity, skin and joint involvement, and corticosteroid tapering [187] (Table 2).